We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
ADLM 2025
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

miRNAs Show Promise for Treatment of Ovarian Cancer

By LabMedica International staff writers
Posted on 21 Aug 2012
Results of a recent study suggest that microRNAs (miRNAs) have excellent therapeutic potential, which justifies continued research efforts designed to turn them into usable anticancer agents.

Investigators at the Georgia Institute of Technology (Atlanta, GA, USA) worked with two well-defined mRNA species, MiR-7 and MiR-128. They conducted a series of controlled experiments in which these two miRNAs--previously implicated in ovarian cancer onset/progression--were individually transfected into a well-defined ovarian cancer (HEY) cell line, and the consequence on global patterns of gene expression was monitored using microarray technology.

The results published in the August 1, 2012, online edition of the journal BMC Medical Genomics revealed that the changes in gene expression induced by the individual miRNAs were functionally coordinated but distinct between the two miRNAs. MiR-7 transfection into ovarian cancer cells induced changes in cell adhesion and other developmental networks previously associated with epithelial-mesenchymal transitions (EMT) and other processes linked with metastasis. In contrast, miR-128 transfection induced changes in cell cycle control and other processes commonly linked with cellular replication.

“Each inserted miRNA created hundreds of thousands of gene expression changes, but only about 20% of them were caused by direct interactions with mRNAs,” said senior author Dr. John McDonald, professor of biology at the Georgia Institute of Technology. “The majority of the changes were indirect – they occurred downstream and were consequences of the initial reactions. miRNAs have evolved for millions of years in order to coordinately regulate hundreds to thousands of genes together on the cellular level. If we can understand which miRNAs affect which suites of genes and their coordinated functions, it could allow clinicians to attack cancer cells on a systems level, rather than going after genes individually”.

Related Links:
Georgia Institute of Technology




Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Urine Chemistry Control
Dropper Urine Chemistry Control
New
Rapid Molecular Testing Device
FlashDetect Flash10

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
21 Aug 2012  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
21 Aug 2012  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
21 Aug 2012  |   BioResearch



PURITAN MEDICAL